GlassScriptPhysician profile
Doris L Hill
NPI 1891914644
$394.08
in general payments reported to CMS, 2019-2025
13 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.87 · 2023: $18.53 · 2024: $62.84 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $106.07 | 2024-2025 | Loreev Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.93 | 2025 | Caplyta |
| Indivior INC. | $43.57 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.93 | 2025 | Qelbree |
| Alkermes, INC. | $21.93 | 2025 | Aristada, Lybalvi |
| Luye Pharma (USA) LTD. | $20.88 | 2025 | Erzofri Extended-Release |
| Redhill Biopharma INC. | $20.65 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $20.58 | 2025 | Austedo Xr |
| Axsome Therapeutics, INC. | $20.19 | 2025 | Auvelity |
| Abbvie INC. | $18.53 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2025 | Cobenfy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.65 | 2021 | |
| Neurocrine Biosciences, INC. | $16.99 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doris Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.